Compare EPAC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | NVAX |
|---|---|---|
| Founded | 1910 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.1B |
| IPO Year | N/A | 1995 |
| Metric | EPAC | NVAX |
|---|---|---|
| Price | $35.95 | $6.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $50.50 | $10.78 |
| AVG Volume (30 Days) | 396.4K | ★ 3.3M |
| Earning Date | 12-17-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 0.98 | N/A |
| EPS | 1.66 | ★ 2.07 |
| Revenue | $615,911,000.00 | ★ $1,064,651,000.00 |
| Revenue This Year | $6.18 | $58.91 |
| Revenue Next Year | $5.58 | N/A |
| P/E Ratio | $23.63 | ★ $3.15 |
| Revenue Growth | 3.91 | ★ 20.27 |
| 52 Week Low | $36.51 | $5.01 |
| 52 Week High | $48.66 | $11.55 |
| Indicator | EPAC | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 43.66 |
| Support Level | $36.80 | $6.36 |
| Resistance Level | $41.73 | $6.76 |
| Average True Range (ATR) | 1.14 | 0.22 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 14.88 | 48.89 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.